CN106520926A - A kind of primer sets and detection method for detecting cancer of pancreas - Google Patents
A kind of primer sets and detection method for detecting cancer of pancreas Download PDFInfo
- Publication number
- CN106520926A CN106520926A CN201610895857.3A CN201610895857A CN106520926A CN 106520926 A CN106520926 A CN 106520926A CN 201610895857 A CN201610895857 A CN 201610895857A CN 106520926 A CN106520926 A CN 106520926A
- Authority
- CN
- China
- Prior art keywords
- primer
- seq
- pancreas
- reverse
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention is provided to detect the primer sets and its detection method of cancer of pancreas, the primer of the present invention includes SEQ ID No.1 SEQ ID No.18, can carry out joint-detection to CK18, CK20, CEA, Vimentin, MUC1, Epcam, Birc5, EGFR and C met genes.By PCR or the method for quantitative fluorescent PCR, Sensitive Detection expression and the expression of target gene can be gone out at short notice;Using the PCR conditions of optimization, make observation result more notable, further improve the applicability of the present invention;Amplified production has specificity, it is ensured that the high accuracy and sensitivity of PCR and fluorescence quantitative PCR detection.Implement the primer sets for cancer of pancreas detection in the present invention, by detecting the expression of patient's sample target gene, can simply, conveniently and accurately diagnosis of pancreatic cancer.
Description
Technical field
The present invention relates to oncogene field, and in particular to a kind of primer sets and detection method for detecting cancer of pancreas.
Background technology
Cancer of pancreas is a kind of digestive system tumor of high malignancy, occupies the 4th of the american cancer cause of death in the world
Scope is also one of most fatal malignant tumour.China's cancer of pancreas the death rate at the 7th to the 8th.
In the last thirty years, cancer of pancreas year survival rate only 2% from improving to 6%, and contemporaneity, all sites tumour
5 years survival rates bring up to 68% from 49%, and the survival rate of certain cancers can reach even more than 90%.The pancreas region of anatomy is hidden
Hide, cancer of pancreas is difficult to early detection and makes a definite diagnosis, patient own Jing during clinical symptoms occurs and transfer occurs, it is difficult to surgery excision.Cancer of pancreas
Due to itself Highly invasive and the drug resistance to chemotherapeutics, traditional operation and chemicotherapy means are difficult to root
Control, therefore with compared with high mortality.Additionally, the incidence of cancer of pancreas is in ascendant trend year by year, recent portion address prediction, according to
Current trend, to year cancer of pancreas by become american cancer associated death it is second largest common the reason for.Find and participate in cancer of pancreas
Generation develops, especially the new biological indicator related to cancer of pancreas early diagnosis and prognosis, for early detection cancer of pancreas
And it is significant to improve the prognosis of Pancreas cancer patients.
Recently, detection of the appearance that circulating tumor cell (Circulating Tumor Cells, CTCs) is detected to patient
Bring new hope.CTCs is to depart from and be displaced to the tumour cell in blood from tumor focus, is malignant tumor patient art
The major reason of recurrence and DISTANT METASTASES IN, and the key factor for causing tumor patient dead afterwards.With other histological specimens such as
Marrow etc. is compared, and periphery blood specimen is easily obtained, and little to patient trauma, is that clinically the ideal sample of conventional detection comes
Source.CTCs detections contribute to the early diagnosis of tumour, judge patient's prognosis, the curative effect of assessment antineoplastic and formulate individuation
Therapeutic scheme.Compared with traditional diagnostic method, CTCs detections can more sensitively find the change of disease, and patient is not had
Side effect.
The detection of CTC is generally carried out by extracting the blood of certain volume.Detection is divided into two classes, including not capturing (be enriched with)
Direct detection and first capture (enrichment) detect afterwards, latter of which for main flow detection method.The side that (enrichment) is detected afterwards is captured first
Method is also classified into two classes, i.e. key player on a team and negative choosing.Key player on a team is mainly (size, close by the physical property of CTC surface markers or cell
Degree) captured;The former is that, based on biomolecular technology and microfluidic chip technology, the latter is based on the original for filtering, be centrifuged
Reason.Negative choosing is then to capture indirectly CTC by leukocyte surface markers thing.But had based on the method that first capture (enrichment) is detected afterwards
Obvious defect.It depends critically upon the expression of tumor cell surface marker thing, therefore cannot capture and do not express surface tumours
The CTC cells of label.
It is another mode of CTC cell detections using the specific gene of the method detection CTC cells of RT-PCR.It is first
The blood of certain volume is first extracted, CTCs is enriched with by way of density gradient centrifugation, is then detected by way of RT-PCR
With this, the mRNA of specific gene, judges that CTCs whether there is, and quantitative to CTCs by detecting the change of CT values.This method inspection
Survey CTCs expenses low, susceptibility is high, and easily automates.
The examination criteria of cancer of pancreas CTCs of RT-PCR method detection at present is also not set up.We are suffered from by detecting cancer of pancreas
The CTCs characterizing genes of person, determine detection method and the examination criteria of cancer of pancreas CTCs.These detection methods and establishment of standard
Contribute to the early diagnosis of tumor patient, judge patient's prognosis, assess antineoplastic (including NK and CAR-T immunization therapies)
Curative effect and formulation individualized treatment scheme.
For the problems referred to above, a kind of high-sensitive polygene combined detection method of present invention exploitation, by joint-detection
9 genes of CK18, CK20, CEA, Vimentin, MUC1, Epcam, Birc5, EGFR and C-met realize the early stage inspection of tumour
Survey.The present invention designs and uses target specific primer group, increases substantially the sensitivity of detection.The recall rate of the detection method can
Reach 95%, be provided simultaneously with that sensitivity is high, specificity is good, quick and precisely the advantages of.
The content of the invention
Present invention aims to the deficiencies in the prior art, there is provided a kind of primer sets and inspection for detecting cancer of pancreas
Survey method,
The purpose of the present invention is achieved through the following technical solutions:A kind of primer sets for detecting cancer of pancreas, comprising:
The primer sets of the present invention can realize the detection of cancer of pancreas by following two methods.
Method 1:PCR method.
(1) 9 pairs of primers described in claim 1 are added separately in single PCR reaction tubes, and add nucleic acid extraction
Thing, reverse transcriptase, RNase inhibitor, archaeal dna polymerase, dNTP;Wherein, the condition of each circulation of PCR reactions is 94 Celsius
Degree, 30s;55 degrees Celsius, 30s;72 degrees Celsius, 10s;
(2) reverse transcription and PCR reactions is carried out, is detected with agarose gel electrophoresis method.
Method 2:Fluorescence quantifying PCR method
(1) 9 pairs of primers described in claim 1 are added separately in single PCR reaction tubes, and add nucleic acid extraction
Thing, reverse transcriptase, RNase inhibitor, archaeal dna polymerase, dNTP;2 × ChamQ SYBR qPCR Master Mix are separately added into,
Wherein, the condition of each circulation of PCR reactions is 95 degrees Celsius, 10s and 60 degree Celsius, 30s;40 circulations;Often pipe sets up three
Individual multiple holes;
(2) reverse transcription and PCR reactions, and real-time detection fluorescence are carried out;
(3) the Ct values calculated according to fluoroscopic examination result, determine whether mark expression of target gene in sample.
The beneficial effects of the present invention is:The present invention is developed for cancer of pancreas early stage by designing Specific PCR primers
The polygene combined detection method of detection.The method:(1) PCR system set up can to CK18, CK20, CEA, Vimentin,
MUC1, Epcam, Birc5, EGFR and C-met gene carries out joint-detection;(2) by carrying out detection pancreas to multiple genes simultaneously
Gland cancer recall rate can reach 98%;(3) sensitivity is high, and the gene expression dose of as little as 1-5 copies can be detected;(4) specificity
By force, normal person or non-Patients with Pancreatic Cancer sample will not produce non-specific signals;(5) detection speed is fast, and simple to operate, expense is low
It is honest and clean.
Description of the drawings
Fig. 1 is healthy human peripheral blood pattern detection feminine gender PCR figures in embodiment.
Fig. 2 is non-Pancreas cancer patients peripheral blood sample detection feminine gender PCR figures in embodiment.
Fig. 3 is non-Pancreas cancer patients cancerous tissue detection feminine gender PCR figures in embodiment.
Fig. 4 is Pancreas cancer patients peripheral blood detection positive PCR figures in embodiment.
Fig. 5 is Pancreas cancer patients tumor tissues detection positive PCR figures in embodiment.
In figure, M.100bp marker;1.B2M;2.CK18;3.CK20;4.CEA;5.Vimentin;6.MUC1;
7.Epcam;8.Birc5;9.EGFR;10.C-met.
Specific embodiment
The present invention drives gene for the tumour in current cancer of pancreas, by joint-detection CK18, CK20, CEA,
9 genes of Vimentin, MUC1, Epcam, Birc5, EGFR and C-met realize the early detection of cancer of pancreas.For inspection at present
Survey method sensitivity is low, and detection process complexity is loaded down with trivial details, long the time required to detection, it is impossible to meet the actual demand of clinical detection.Pin
To the problems referred to above, a whole set of specific primer group for detecting above-mentioned 9 genes is designed.
Specificity amplification primer is designed according to the reference sequences of above-mentioned 9 genes, its PCR primer length optimum is in 180-
Between 200bp, not higher than 60 degree of annealing temperature, G/C content meets the requirement of general primer-design software between 40-60%.
By using real-time fluorescence PCR reaction detection system, realizing the highly sensitive detection of multiple gene associations, the following institute of its detection method
State.
The present invention is further described in conjunction with the accompanying drawings and embodiments.As do not specialized part, can be according to this area skill
Familiar to art personnel institute《Molecule can grand experiment guide》The third edition (Cold Spring Harbor laboratory Press),
《Cell experiment guide》(Science Press, Beijing, China, calendar year 2001),《RNA experimental technique handbooks》(Science Press, north
Capital, China, 2004),《Immunoassay technology》1991) (Science Press, Beijing, China, laboratory manual and this paper such as
In cited bibliography, listed method is implementing.Wherein, (tape label) probe used, primer can be entrusted
The synthesis of support Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.
With reference to embodiment, the invention will be further described.
Embodiment 1:Gene selects
Multiple studies have shown that, single-gene examination susceptibility is about 20-60%, is mostly used in the single of tumour early screening
Genetic test, its detection sensitivity or specificity it is low, it is impossible to meet clinical needs.Can be effective using polygene combined detection
Solve the problems, such as that susceptibility is low, improve the degree of accuracy of tumour early screening and diagnosis.Zhou J et al. (Zhou J, Hu L, Yu
Z,et al.Marker expression incirculating cancer cells of pancreatic
cancerpatients.J Surg Res 2011;171:631 6.) while detection hTERT, CK20, C-met, CEA gene, knot
Fruit shows four genes of joint-detection and detects far above single-gene for the susceptibility that cancer of pancreas is early diagnosed.In order to improve early stage
The recall rate of tumour, improves the cure rate of tumor patient, improves patient's prognosis, our difference tables to cancer of pancreas and normal structure
Screened up to gene.We by a large amount of control experiments find CK18, CK20, CEA, Vimentin, MUC1, Epcam,
The genome of Birc5, EGFR and C-met composition has higher recall rate to cancer of pancreas, reaches 98%, relative to existing inspection
Survey technology, generates unexpected technique effect, with significant progressive.
Embodiment 2:Primer screening
(1) design primer a1~a3, b1~b3, c1~c3, d1~d3, e1~e3, f1~f3, g1~g3, h1~h3, i1
~i3, specially:Target gene A-I sequences are analyzed using bioinformatics software, it is special using sequence analysis software design
Specific primer group, using each pairing specificity of the primer in human genome of NCBI primers search software detection, separately designs out 3
To specificity amplification primer a1~a3, b1~b3, c1~c3, d1~d3, e1~e3, f1~f3, g1~g3, h1~h3, i1~
i3;
Table 1:PCR detection primers
(2) process of peripheral blood sample
The Pancreas cancer patients peripheral blood that certain hospital accepts simultaneously Jing proved by pathology for medical treatment is collected, in 7 points of early morning, on an empty stomach, Jing ulnar veins are adopted
Collection new blood, deposits in anticoagulant tube, shakes up, preservation≤4hr under normal temperature.
Whole blood sample in anticoagulant tube is added equal-volume PBS (pH7.0) by 2.1,5min is centrifuged in room temperature 3000rpm, goes
Except upper plasma;
2.2 add equal-volume ammonium chloride erythrocyte cracked liquid (being purchased from the green skies), mix in room temperature 200rpm centrifugation 8min
After even, 5min, supernatant discarded are centrifuged with 3000rpm room temperatures;
2.3 by lower floor's haemocyte and physiological saline according to volume ratio 1:2~2:After 1 mixing, Ficoll separating liquids are added, mixed
The volume ratio that liquid is closed with Ficoll separating liquids is 1:2~2:1, centrifugal force is 700g, and 20~40min is centrifuged;
Supernatant is abandoned in 2.4 suctions, takes cell precipitation, is washed, that is, is obtained PBMC;
2.5 take PBMC for nucleic acid extraction, and unnecessary PBMC is resuspended with RNA protective agents, are stored in -20 degree.
(3) extraction of nucleic acid
3.1 take not more than 5 × 105PBMC, add 250 μ LBuffer RLT Plus, piping and druming mix;
Lysate is transferred to gDNA by 3.2 to be removed in centrifugal type post, 8000 × g (10,000rpm) centrifugation 30s.Collect stream
Liquid is worn, centrifugal column is abandoned;
To flowing through in liquid, piping and druming is mixed 70% ethanol (350 μ L) of 3.3 1 times of volume of addition;
Sample is transferred to RNeasyMinElute centrifugal columns by 3.4, covers tightly lid, 8000 × g (10,000rpm) centrifugations
15s, abandoned stream wear liquid;
3.5 add 700 μ L Buffer RW1 in RNeasyMinElute centrifugal columns, cover tightly lid, 8000 × g (10,
15s is centrifuged 000rpm), abandoned stream wears liquid;
3.6 add 500 μ L Buffer RPE in RNeasyMinElute centrifugal columns, cover tightly lid, 8000 × g (10,
15s is centrifuged 000rpm), abandoned stream wears liquid;
3.7 are placed in RNeasyMinElute centrifugal columns in new 2mL collecting pipes, open lid, and centrifugation 5min, makes at full speed
Ethanol volatilizees;
3.8 are placed in RNeasyMinElute centrifugal columns in new 1.5mL collecting pipes, add 20 μ LRNase-free
H2O, covers tightly lid, at full speed centrifugation 1min eluted rnas.
(4) acquisition of template cDNA
4.1 accurately measure sample RNA concentration;
4.2 prepare reverse transcription system in strict accordance with cDNA reverse transcription reagent box specifications on ice;
Composition | Volume |
5×Mix | 8μL |
RNA | 500ng |
RNase-free H2O | To 40 μ L |
4.3 soft mixing above reaction systems, and the of short duration centrifugation of centrifuge is utilized, 55 degree of 20min, 85 degree of 2min are obtained
Template cDNA;
(5) regular-PCR amplification
Reaction system is configured with Taq archaeal dna polymerases, with primer be a-i and people's reference gene (B2M) enters performing PCR amplification respectively
Sample, 1% gel detection of product;
Amplification system
Composition | Volume |
2×Mix | 10μL |
cDNA | 1μL |
Primer-F | 0.8μL |
Primer-R | 0.8μL |
RNase-free H2O | 7.4μL |
PCR reaction conditions are 95 DEG C of denaturations 3 minutes, 1 circulation;95 DEG C of denaturation 20 seconds, 55 DEG C are annealed 20 seconds, and 72 DEG C are prolonged
Stretch 10 seconds, 35 circulations;72 DEG C extend 7 minutes.
(6) fluorescence real-time quantitative PCR amplification
Specifically draw a group a-i according to what is designed, expanded by quantitative fluorescent PCR, system is as follows:
Composition | Volume |
2×ChamQ SYBR qPCRMaster Mix | 10μL |
cDNA | 2μL |
Primer-F | 0.4μL |
Primer-R | 0.4μL |
RNase-free H2O | 7.2μL |
Total | 20μL |
95 DEG C of denaturations 20s, 1 circulation;95 DEG C of 10s, 60 DEG C of 30s, 40 circulations;Often pipe sets up three multiple holes;
According to step 5 and 6 pcr results, following primer sets are filtered out, be used for detecting the primer of cancer of pancreas as the present invention
Group.
Embodiment 3:Compliance test result
According to the selection result of embodiment 2,200 tumor samples are detected using the primer sets described in following table.
Wherein, the forward primer of CK8 is CGCCTGGAAGGGCTGACCGA, and reverse primer is
GTTGGCAATATCCTCGTACT;The forward primer of N-cadherin is CCTTAACTGAGGAGTCAGTG, and reverse primer is
CAGACCTGATCCTGACAAGC;The forward primer of VEGF is GTGCCCGCTGCTGTCTAATG, and reverse primer is
CACATCTGCAAGTACGTTCG;The forward primer of VEGFR2 is GAGAAGCAGAGCCATGTGGT, and reverse primer is
GCACTCTTCCTCCAACTGCC。
The recall rate of 1~No. 9 primer sets as shown above, as can be seen from the table, in primer sets, with primer quantity
Increase, its recall rate can be improved to a certain extent.Further, by comparing 5~No. 9 primer sets it is found that primer
Combination in group is had a major impact for the height of recall rate.Simultaneously in the case of identical detection gene dosage, No. 5 primer sets
Recall rate be higher than 6~No. 9 primer sets.Therefore, the assortment of genes of our preferably No. 5 primer sets is used for the detection of cancer of pancreas.Enter
One step finds that by studying, in No. 5 primer sets, the expression of CK18, CK20 can point out the tumour of epithelial cell origin;Epidermal growth
Factor acceptor (EGFR) is played an important role in the generation evolution of numerous malignant tumours, becomes current tumor research new
One of focus;C-met is related to the growth of tumour cell, invasion and attack, transfer and apoptosis as receptor tyrosine kinase;Vimentin
It is the tumor marker in normal mesenchymal cell and its source, during EMT is participated in, and plays critical effect;
EPCAM belongs to epithelial cell adhesion molecule, plays and act on during carcinogenesis;Birc5 is IAP, swollen
Unconventionality expression in knurl;MUC 1 plays an important role in the progress of inflammation and tumour;CEA is a kind of broad-spectrum tumor mark.
From the foregoing, it will be observed that the present invention is not that 9 pairs of primers are carried out simple superposition combination, 9 pairs of primers complement each other, functionally prop up each other
Hold so that recall rate is improved significantly, achieve unexpected technique effect.In sum, select in the present invention
Gene is related to the aspects such as the metabolism of tumour, propagation, invasion and attack, more can comprehensively detect the cell biological characteristics of cancer of pancreas.
Embodiment 4:Specificity analysis
According to the selection result of embodiment 2, using the primer sets described in upper table to normal person's peripheral blood sample (Fig. 1), non-
The peripheral blood (Fig. 2) and tumor tissues sample (Fig. 3) of Patients with Pancreatic Cancer, the peripheral blood (Fig. 4) of Patients with Pancreatic Cancer and tumor sample
(Fig. 5) detected.As a result as Figure 1-5, primer sets described as seen from the figure are in normal human peripheral blood (Fig. 1), non-pancreas
The low expression of gene is detected in the peripheral blood (Fig. 2) and tumor tissues sample (Fig. 3) of gland cancer patient or is not expressed.In cancer of pancreas
In the peripheral blood (Fig. 4) of patient and tumor tissues, (Fig. 5) can detect that the expression of multiple genes, respectively 5/9 and 6/9, explanation
Heretofore described primer sets have the specificity of height.
Claims (3)
1. a kind of primer sets for detecting cancer of pancreas, it is characterised in that the primer sets can be comprising a~i9 to primer, institute
The forward primer of primer a is stated as shown in SEQ ID No.1, as shown in SEQ ID No.2, primer b is just for the reverse primer of primer a
To primer as shown in SEQ ID No.3, the reverse primer of primer b as shown in SEQ ID No.4, the forward primer such as SEQ of primer c
Shown in ID No.5, the reverse primer of primer c as shown in SEQ ID No.6, the forward primer such as SEQ ID No.7 institutes of primer d
Show, the reverse primer of primer d as shown in SEQ ID No.8, the forward primer of primer e as shown in SEQ ID No.9, primer e's
Reverse primer as shown in SEQ ID No.10, the forward primer of primer f as shown in SEQ ID No.11, the reverse primer of primer f
As shown in SEQ ID No.12, the forward primer of primer g as shown in SEQ ID No.13, the reverse primer such as SEQ ID of primer g
Shown in No.14, the forward primer of primer h as shown in SEQ ID No.15, the reverse primer such as SEQ ID No.16 institutes of primer h
Show, as shown in SEQ ID No.17, the reverse primer of primer i is as shown in SEQ ID No.18 for the forward primer of primer i.
2. primer sets described in a kind of claim 1 detect the PCR method of cancer of pancreas, it is characterised in that comprise the steps:
(1) 9 pairs of primers described in claim 1 are added separately in single PCR reaction tubes, and add nucleic acid extractive,
Reverse transcriptase, RNase inhibitor, archaeal dna polymerase, dNTP;Wherein, PCR reaction each circulation condition be 94 degrees Celsius,
30s;55 degrees Celsius, 30s;72 degrees Celsius, 10s;
(2) reverse transcription and PCR reactions is carried out, is detected with agarose gel electrophoresis method.
3. primer sets described in a kind of claim 1 detect the fluorescence quantifying PCR method of cancer of pancreas, it is characterised in that including as follows
Step:
(1) 9 pairs of primers described in claim 1 are added separately in single PCR reaction tubes, and add nucleic acid extractive,
Reverse transcriptase, RNase inhibitor, archaeal dna polymerase, dNTP;2 × ChamQ SYBR qPCR Master Mix are separately added into, its
In, the condition of each circulation of PCR reactions is 95 degrees Celsius, 10s and 60 degree Celsius, 30s;40 circulations;Often pipe sets up three
Multiple holes;
(2) reverse transcription and PCR reactions, and real-time detection fluorescence are carried out;
(3) the Ct values calculated according to fluoroscopic examination result, determine whether mark expression of target gene in sample.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610895857.3A CN106520926A (en) | 2016-10-14 | 2016-10-14 | A kind of primer sets and detection method for detecting cancer of pancreas |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610895857.3A CN106520926A (en) | 2016-10-14 | 2016-10-14 | A kind of primer sets and detection method for detecting cancer of pancreas |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106520926A true CN106520926A (en) | 2017-03-22 |
Family
ID=58331773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610895857.3A Pending CN106520926A (en) | 2016-10-14 | 2016-10-14 | A kind of primer sets and detection method for detecting cancer of pancreas |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106520926A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014193999A2 (en) * | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
US20160041153A1 (en) * | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
-
2016
- 2016-10-14 CN CN201610895857.3A patent/CN106520926A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160041153A1 (en) * | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
WO2014193999A2 (en) * | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
Non-Patent Citations (2)
Title |
---|
JIAHUA ZHOU等: "Marker Expression in Circulating Cancer Cells of Pancreatic Cancer Patients", 《JOURNAL OF SURGICAL RESEARCH》 * |
TAISUKE IMAMURA等: "Liquid biopsy in patients with pancreatic cancer:Circulating tumor cell and cell-free nucleic acids", 《WORLD JOURNAL OF GASTROENTEROLOGY》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Economopoulou et al. | Liquid biopsy: an emerging prognostic and predictive tool in head and neck squamous cell carcinoma (HNSCC). Focus on circulating tumor cells (CTCs) | |
Li et al. | Molecular characterization of circulating tumor cells—from bench to bedside | |
Liu et al. | Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer | |
BRPI0709397A2 (en) | primary cell propagation | |
US20070048750A1 (en) | Rapid efficacy assessment method for lung cancer therapy | |
CN107034301A (en) | A kind of detection Lung neoplasm is benign or pernicious kit and its application | |
CN103074430B (en) | Special primer, kit and method for testing miRNA-155 in bladder cancer urine | |
CN106191055A (en) | A kind of non-small cell lung carcinoma marker, detectable and test kit | |
CN103074431B (en) | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum | |
CN106834447A (en) | A kind of primer sets and detection method for detecting neuroblastoma | |
CN106399527A (en) | Primer group for detecting renal cancer and detecting method thereof | |
CN105671179B (en) | application of serum microRNA in liver cancer diagnosis and diagnosis kit | |
CN106544416A (en) | A kind of primer sets and detection method for detecting gastric cancer | |
CN104450702B (en) | A kind of Serum miRNA biomarker composition and application | |
CN106520924A (en) | Primer set and detection method for detecting ovarian cancer | |
CN110257514A (en) | A kind of new cancer of the esophagus blood miRNA marker and its application | |
CN106636440B (en) | Blood plasma microRNAs is used to prepare the purposes of the diagnostic reagent of patients with lung adenocarcinoma in sieving and diagnosis male population | |
CN102021169A (en) | Serum/plasma miRNA composition and use thereof | |
CN108424962A (en) | The miRNA detection markers and its diagnostic kit of mesangial proliferative glomerulonephritis | |
CN106755459A (en) | A kind of primer sets and detection method for detecting breast cancer | |
CN106434936A (en) | Primer group used for detecting lung cancer and detection method thereof | |
CN106520926A (en) | A kind of primer sets and detection method for detecting cancer of pancreas | |
CN106498041A (en) | A kind of primer sets and detection method for detecting cervical cancer | |
CN106367509A (en) | LOC100128675 serving as molecular marker for detecting prostate cancer and application of molecular marker to diagnostic kit | |
CN103589786B (en) | Method, test kit and the primer of detection RRM1 mRNA relative expression quantity and probe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
RJ01 | Rejection of invention patent application after publication |